Next Article in Journal
Lactoferrin: A Critical Player in Neonatal Host Defense
Previous Article in Journal
Carbohydrate Knowledge and Expectations of Nutritional Support among Five Ethnic Groups Living in New Zealand with Pre- and Type 2 Diabetes: A Qualitative Study
Previous Article in Special Issue
Flash Glucose Monitoring: A Review of the Literature with a Special Focus on Type 1 Diabetes
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessArticle
Nutrients 2018, 10(9), 1226; https://doi.org/10.3390/nu10091226

Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels

1
Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
2
Center for Translational Research on Inflammatory Diseases, Michael E. DeBakey VA Medical Center, 2002 Holcombe Blvd, Houston, TX 77030, USA
3
Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA
4
New Mexico VA Health Care System, 1501 San Pedro SE, Albuquerque, NM 87108, USA
5
Division of Mathematics and Statistics, University of New Mexico School of Medicine, Albuquerque, NM 87108, USA
6
Department of Endocrinology and Metabolism, University Campus Biomedico of Rome, Via Alvaro del Portillo 21040, 00128 Rome, Italy
*
Author to whom correspondence should be addressed.
Received: 30 July 2018 / Revised: 27 August 2018 / Accepted: 31 August 2018 / Published: 4 September 2018
(This article belongs to the Special Issue Steroid Hormones and Human Health)
Full-Text   |   PDF [1924 KB, uploaded 4 September 2018]   |  

Abstract

Estradiol (E2), mainly produced from Testosterone (T) in men, promotes visceral lipolysis. However, high visceral fat and hyperestrogenemia are features of obese hypogonadal (HG) men. Our study objectives are to evaluate relationships between circulating E2 and: (1) fat mass; (2) Estrogen Receptor α (ESR1) expression in subcutaneous adipose tissue; (3) changes in body fat after 6 months (M) of T therapy in HG men. Hypotheses: (1) existence of a range of circulating E2 associated with better body composition; (2) serum E2 determines tissue E2 sensitivity which affects response to T therapy. Men 40–74 years old, T < 300 (ng/dL), given T-cypionate for 6 months. Subjects were divided into 4-E2 categories: (1) <10.0; (2) 10.0–15.9; (3) 16.0–19.9; (4) ≥20.0 (pg/mL). Body composition (DXA), fat biopsies (liposuction), gene expression (qPCR), serum E2 and T (LC/MS), at baseline and 6 months. We enrolled 105 men; 90 completed the study. Group 2 had lower total and truncal fat mass (p < 0.01) but higher % lean mass (p < 0.001). ESR1 mRNA was the highest in group 1 (p = 0.01). At 6 months, group 1 had higher reduction in total (p = 0.03) and truncal (p = 0.01) fat. In conclusion, serum E2 = 10–15.9 (pg/mL) is associated with the best body composition profile in HG men; however, those with E2 < 10 (pg/mL) had the best response (greater fat loss) to T replacement possibly because of greater E2 sensitivity. View Full-Text
Keywords: oestrogen receptor α; testosterone; estradiol; fat mass; obesity; hypogonadism oestrogen receptor α; testosterone; estradiol; fat mass; obesity; hypogonadism
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Colleluori, G.; Aguirre, L.E.; Qualls, C.; Chen, R.; Napoli, N.; Villareal, D.T.; Armamento-Villareal, R. Adipocytes ESR1 Expression, Body Fat and Response to Testosterone Therapy in Hypogonadal Men Vary According to Estradiol Levels. Nutrients 2018, 10, 1226.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top